Pleural Mesothelioma: Symptoms & Treatment
Pleural mesothelioma accounts for 81% of US cases (CDC 2003-2022). Learn about symptoms, staging, treatment options, and SEER 5-year survival of 12%.
What Is Pleural Mesothelioma?
Pleural mesothelioma is a cancer of the pleura, the thin, two-layered membrane surrounding the lungs. It accounts for 81% of US mesothelioma diagnoses (51,526 of 63,620 cases between 2003 and 2022, per CDC US Cancer Statistics), making it by far the most common form of this asbestos-related cancer.
The pleura consists of two layers:
- Parietal pleura: Lines the chest wall and diaphragm
- Visceral pleura: Covers the lungs
Between these layers is a small amount of fluid that allows the lungs to expand and contract smoothly during breathing. Pleural mesothelioma develops when inhaled asbestos fibers lodge in this lining and, over decades, cause malignant cellular changes.
Causes and Risk Factors
The Role of Asbestos
Asbestos is the only known cause of pleural mesothelioma. When asbestos-containing materials are disturbed, microscopic fibers become airborne and can penetrate deep into lung tissue, eventually reaching the pleural lining.
The body cannot break down or expel asbestos fibers. Over time, the fibers cause:
- Chronic inflammation
- Genetic mutations in mesothelial cells
- Oxidative stress and cellular damage
- Eventually, malignant transformation
Who Is Most Exposed
Symptoms of Pleural Mesothelioma
Symptoms typically don’t appear until the disease has progressed, which is why 65% of cases are diagnosed at Stage 3 or 4.
How Early Symptoms Present
How Symptoms Progress
- Difficulty swallowing (dysphagia)
- Night sweats
- Unexplained weight loss
- Pleural effusion (fluid buildup around lungs)
- Lumps under the skin on the chest
- Facial or arm swelling
Why Symptoms Are Often Missed
Early pleural mesothelioma symptoms mimic common conditions like pneumonia, bronchitis, COPD, or even normal aging. Without known asbestos exposure history, physicians may not initially suspect mesothelioma.
If you have a history of asbestos exposure and experience respiratory symptoms, inform your healthcare provider about your exposure history. This context significantly changes how symptoms should be evaluated.
Diagnosis
How Diagnosis Works
Diagnosis typically involves four steps. Clinicians begin with medical history and physical exam, including a detailed occupational history. Imaging (chest X-ray, CT, PET, and sometimes MRI) characterizes tumor extent. A tissue biopsy via thoracoscopy, thoracotomy, or CT-guided needle is required for definitive diagnosis. Finally, immunohistochemistry distinguishes mesothelioma from lung adenocarcinoma and other chest cancers. Mesothelioma-focused centers such as Memorial Sloan Kettering, Dana-Farber, and the University of Pennsylvania Abramson Cancer Center maintain dedicated pathology review panels.
Cell Types Seen Under the Microscope
| Cell Type | Frequency | Characteristics | Prognosis |
|---|---|---|---|
| Epithelioid | 50-70% | Most common; cells resemble normal tissue | Best |
| Sarcomatoid | 10-20% | Spindle-shaped cells; more aggressive | Poorest |
| Biphasic | 20-35% | Mix of both cell types | Intermediate |
Staging
Pleural mesothelioma uses the TNM staging system:
- T (Tumor): Size and extent of the primary tumor
- N (Nodes): Lymph node involvement
- M (Metastasis): Distant spread
| Stage | Description | Typical Treatment | Median Survival | 2-Year |
|---|---|---|---|---|
| Stage 1 | Localized, confined to pleural lining on one side | Surgery often possible (EPP or P/D) + chemotherapy | ~21 months | 39% |
| Stage 2 | Regional, spread beyond pleura but on one side | Surgery may be possible + chemotherapy | ~19 months | 39% |
| Stage 3 | Advanced regional, often involves lymph nodes | Chemo + immunotherapy; surgery for some | ~18 months | 41% |
| Stage 4 | Distant metastasis, spread beyond the chest | Chemo, immunotherapy, palliative care | ~12 months | 31% |
Only 9% of patients receive a Stage 1 diagnosis. This underscores the importance of reporting asbestos exposure history to healthcare providers.
Treatment Options
Who Qualifies for Surgery
Surgery is typically an option only for early-stage patients (approximately 20% of diagnoses) who are healthy enough to tolerate the procedure. The MARS-2 trial reported in 2024 found that extended pleurectomy/decortication did not improve survival over chemotherapy alone in randomized comparison, which has shifted practice toward lung-sparing approaches and careful patient selection.
| Procedure | What It Removes | Best For | Recovery |
|---|---|---|---|
| Extrapleural Pneumonectomy (EPP) | Removes affected lung, pleural lining, part of diaphragm, and pericardium | Patients in good overall health | Longer |
| Pleurectomy/Decortication (P/D) | Removes pleural lining while preserving the lung | Most surgical candidates | Faster |
Chemotherapy Regimens
The standard first-line regimen combines pemetrexed (Alimta, FDA-approved for mesothelioma in 2004) with cisplatin or carboplatin. This combination has been the standard of care for over 15 years.
Immunotherapy Approaches
Immunotherapy represents the first major advancement in mesothelioma treatment in 15 years. In October 2020, the FDA approved Opdivo (nivolumab) combined with Yervoy (ipilimumab) for first-line treatment.
Radiation Therapy Uses
Radiation is typically used in combination with surgery and chemotherapy, or for palliative care to reduce tumor size, kill remaining cancer cells after surgery, and relieve pain and symptoms.
Multimodal Treatment Outcomes
Patients who receive multimodal treatment, combining surgery, chemotherapy, and sometimes immunotherapy, achieve the best outcomes. Early-stage cohorts treated with surgery plus chemotherapy and radiation report median survival of 21 to 24 months in published series (compared to 13 months overall), with a subset living well beyond five years.
Survival Rates and Prognosis
Factors That Affect Prognosis
| Prognostic Factor | Effect on Prognosis |
|---|---|
| Earlier stage at diagnosis | Positive |
| Epithelioid cell type | Positive |
| Good overall health | Positive |
| Younger age | Positive |
| Female gender | Positive |
| Access to specialized treatment | Positive |
| Advanced stage (3-4) | Negative |
| Sarcomatoid or biphasic cell type | Negative |
| Poor performance status | Negative |
| Elevated blood LDH | Negative |
Living with Pleural Mesothelioma
Finding Specialized Care
Clinical Trials
Clinical trials provide access to emerging treatments before they’re widely available. Resources include:
- ClinicalTrials.gov
- NCI Cancer Information Service
- Mesothelioma treatment center trial programs
Support Resources
- Patient advocacy organizations
- Support groups for patients and caregivers
- Palliative care services
- Social workers specializing in cancer care
Prevention
For Current Workers
For Those with Past Exposure
Reader Q&A
Frequently Asked Questions
What treatment options are available for my stage?
Stage 1-2 patients may be candidates for surgery (EPP or P/D) combined with chemotherapy and possibly radiation. Stage 3-4 typically involves chemotherapy and immunotherapy. Ask about clinical trials at any stage.
Am I a candidate for immunotherapy?
Nivolumab plus ipilimumab is now FDA-approved as first-line treatment. Your oncologist will consider your cell type, overall health, and treatment goals. Sarcomatoid tumors may particularly benefit from immunotherapy.
Should I get a second opinion?
Yes, particularly at a specialized mesothelioma center. These centers have more experience, access to clinical trials, and multidisciplinary teams that can identify treatment options you might not otherwise hear about.
What factors affect my prognosis?
Key factors include stage at diagnosis, cell type (epithelioid is best), overall health, age, gender (women have slightly better outcomes), and treatment received. Multimodal treatment at specialized centers produces the best outcomes.
What is the best treatment for pleural mesothelioma?
Evidence from major cancer centers and recent ASCO guidelines shows there is no single “best” treatment for pleural mesothelioma, because outcomes depend heavily on stage, cell type, overall health, and whether tumors can be removed with surgery. For people with resectable disease, multimodal therapy that combines surgery (such as pleurectomy and decortication or extrapleural pneumonectomy) with chemotherapy, radiation, and sometimes immunotherapy is associated with the longest survival in published studies. For unresectable pleural mesothelioma, first-line systemic treatment now commonly involves immunotherapy with nivolumab plus ipilimumab or chemoimmunotherapy such as pembrolizumab with pemetrexed and a platinum drug, which in trials improved 2-year survival compared with chemotherapy alone. Chemotherapy with pemetrexed and cisplatin or carboplatin remains a core option across stages, and palliative procedures (like draining chest fluid, pleurodesis, or targeted radiation) play a key role in symptom relief and quality of life. People with mesothelioma are often encouraged in the medical literature to consider clinical trials, since ongoing studies are testing newer immunotherapies, targeted drugs, and advanced radiation or surgical techniques.
What is the first symptom of mesothelioma?
Early symptoms of mesothelioma often appear years or decades after asbestos exposure and vary by type, with no single first symptom reported universally. Common early signs across types include fatigue, unexplained weight loss, shortness of breath, persistent cough, and chest or abdominal pain. For pleural mesothelioma, shortness of breath and dry cough predominate; peritoneal cases frequently involve abdominal bloating or pain; rarer pericardial and testicular forms may present with chest pain or testicular swelling, respectively. These symptoms are typically mild and mimic other conditions.
What is the life expectancy of someone with pleural mesothelioma?
Life expectancy for people with pleural mesothelioma is typically shortened, but ranges widely based on stage, treatment, age, and overall health. Across major reviews, average survival with treatment often falls between 12 and 21 months, with several advocacy sites citing around 17 to 18 months as a common estimate. Without active cancer treatment, reported averages usually drop to about 4 to 12 months. Population data from the American Cancer Society show 5‑year relative survival rates of 23% for localized pleural mesothelioma, 15% for regional disease, and 11% for distant spread, with about 15% across all stages combined. Individual outcomes can be much shorter or longer than these averages, particularly for people who qualify for surgery or newer multimodal therapies.
How long does it take malignant pleural mesothelioma to appear after first asbestos exposure?
Latency periods for malignant pleural mesothelioma after first asbestos exposure range from 14 to 72 years, with a mean of 48.7 years and median of 51 years in a study of 312 cases from Italy. Occupational groups with high-intensity exposure, such as insulators (mean 29.6 years) and dock workers (35.4 years), show shorter latencies than shipyard workers (49.4 years) or those with domestic exposure (51.7 years). Other studies report median latencies of 33.7 to 34 years, with 96% of cases occurring at least 20 years post-exposure. Factors like exposure intensity, duration, and type influence variability, though no single timeline applies universally.